thalidomide has been researched along with Lupus Erythematosus, Systemic in 39 studies
Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.
Lupus Erythematosus, Systemic: A chronic, relapsing, inflammatory, and often febrile multisystemic disorder of connective tissue, characterized principally by involvement of the skin, joints, kidneys, and serosal membranes. It is of unknown etiology, but is thought to represent a failure of the regulatory mechanisms of the autoimmune system. The disease is marked by a wide range of system dysfunctions, an elevated erythrocyte sedimentation rate, and the formation of LE cells in the blood or bone marrow.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Five patients including 4 patients with lupus erythematosus (1 discoid lupus, 1 subacute lupus and 2 systemic lupus erythematosus) and one patient with a severe atopic dermatitis, all without previous history of vascular events, developed an arterial thrombosis (2 cases) or a venous thrombosis (3 cases), severe in 4 cases, few days or weeks after the onset of thalidomide treatment (50 to 100 mg daily)." | 7.70 | [Thalidomide and thrombosis]. ( Bachelez, H; Carsuzaa, F; Cavelier-Balloy, B; Dubertret, L; Flageul, B; Wallach, D, 2000) |
| "Thalidomide treatment had no significant effect on markers of apoptosis including sunburn cell formation and terminal deoxynucleotidyl transferase-mediated biotinylated deoxyuridine triphosphate nick end labelling, which identifies single-strand breaks in DNA." | 5.32 | Photoprotection by thalidomide in patients with chronic cutaneous and systemic lupus erythematosus: discordant effects on minimal erythema dose and sunburn cell formation. ( Cummins, DL; Gaspari, AA, 2004) |
| "This review article discusses the thalidomide therapy of diseases such as systemic sclerosis, rheumatoid arthritis, Behçet syndrome, lupus erythematosus disseminatus and graft-versus-host disease." | 4.82 | [Thalidomide--a new prospective therapy in rheumatology and transplantation]. ( Dziedziczko, A; Pałgan, I; Pałgan, K, 2003) |
| "English-language articles were identified through a MEDLINE search (1966-February 2001); key terms included thalidomide, child, graft-versus-host disease, cancer, HIV, Crohn's disease, Behçet's disease, and lupus erythematosus." | 4.81 | Thalidomide use in pediatric patients. ( Bessmertny, O; Pham, T, 2002) |
| "Five patients including 4 patients with lupus erythematosus (1 discoid lupus, 1 subacute lupus and 2 systemic lupus erythematosus) and one patient with a severe atopic dermatitis, all without previous history of vascular events, developed an arterial thrombosis (2 cases) or a venous thrombosis (3 cases), severe in 4 cases, few days or weeks after the onset of thalidomide treatment (50 to 100 mg daily)." | 3.70 | [Thalidomide and thrombosis]. ( Bachelez, H; Carsuzaa, F; Cavelier-Balloy, B; Dubertret, L; Flageul, B; Wallach, D, 2000) |
| "Thalidomide has shown exceptional results in systemic/cutaneous lupus erythematosus(SLE/CLE)." | 2.72 | Thalidomide and Lenalidomide for Refractory Systemic/Cutaneous Lupus Erythematosus Treatment: A Narrative Review of Literature for Clinical Practice. ( Aikawa, NE; Bonfa, E; Heise, CO; Pasoto, SG; Romiti, R; Silva, CA; Yuki, EFN, 2021) |
| "Although systemic lupus erythematosus (SLE) is associated with lymphoid malignancies, concurrent multiple myeloma and SLE are rare." | 2.45 | Multiple myeloma and systemic lupus erythematosus in a young woman. ( Horvath, W; Irani, F; Okoli, K, 2009) |
| "Thalidomide has been shown to be an effective treatment for cutaneous forms of lupus erythematous refractory to other therapies." | 2.41 | Update on therapy--thalidomide in the treatment of lupus. ( Hughes, GR; Karim, MY; Khamashta, MA; Ruiz-Irastorza, G, 2001) |
| "A 69-year-old female patient with breast cancer experienced severe skin itching and rashes on the face, anterior chest wall, back, and trunk for two days before admission." | 1.72 | A case report of secondary synchronous diagnosis of multiple myeloma and systemic lupus erythematosus after breast cancer treatment: A CARE-compliant article. ( Chen, PH; Huang, KP; Lin, CH; Lin, CY; Ni, YL; Tung, HH, 2022) |
| "Thalidomide levels were determined by high-performance liquid chromatography/tandem mass spectrometry." | 1.62 | One-year prospective nerve conduction study of thalidomide neuropathy in lupus erythematosus: Incidence, coasting effect and drug plasma levels. ( Aikawa, NE; Arnone, M; Bonfa, E; Heise, CO; Kupa, LVK; Pasoto, SG; Pedrosa, TDN; Romiti, R; Silva, CAAD; Soares, R; Yuki, EFN, 2021) |
| "Lenalidomide therapy was started after the diagnosis and the patient had a favorable outcome." | 1.46 | Utility of osteosclerotic lesion biopsy in diagnosis of POEMS syndrome: A case report. ( Akiyama, H; Hara, D; Hasegawa, Y; Hoshikawa, M; Nukui, S; Shimizu, T, 2017) |
| "Lenalidomide was well tolerated." | 1.46 | Lenalidomide for refractory cutaneous manifestations of pediatric systemic lupus erythematosus. ( Rabinovich, CE; Schanberg, LE; Wershba, EC; Wu, EY, 2017) |
| "Lenalidomide is a thalidomide analogue that may serve as an adjunctive therapy for treatment-refractory cutaneous lupus erythematosus (CLE)." | 1.38 | Lenalidomide therapy in treatment-refractory cutaneous lupus erythematosus: histologic and circulating leukocyte profile and potential risk of a systemic lupus flare. ( Braunstein, I; Goodman, NG; Kovarik, CL; Krathen, M; Luning Prak, E; Okawa, J; Rosenbach, M; Shah, A; Werth, VP, 2012) |
| "Osseous metaplasia has recently been described in several cases of nephrogenic systemic fibrosis, sometimes in association with unusual clinical features such as painful hyperkeratotic spicules, palpable bony masses, and disease regression." | 1.36 | Osseous metaplasia late in the course of nephrogenic systemic fibrosis. ( Bayliss, SJ; Berk, DR; Lu, D; Miller, A; Scarlett, D; Wippold, FJ, 2010) |
| "Thalidomide is an anti-inflammatory agent and an immunomodulator that inhibits the production of tumor necrosis factor alpha." | 1.32 | Low-dose thalidomide therapy for refractory cutaneous lesions of lupus erythematosus. ( Fleischer, AB; Grummer, SE; Housman, TS; Jorizzo, JL; McCarty, MA; Sutej, PG, 2003) |
| "Thalidomide treatment had no significant effect on markers of apoptosis including sunburn cell formation and terminal deoxynucleotidyl transferase-mediated biotinylated deoxyuridine triphosphate nick end labelling, which identifies single-strand breaks in DNA." | 1.32 | Photoprotection by thalidomide in patients with chronic cutaneous and systemic lupus erythematosus: discordant effects on minimal erythema dose and sunburn cell formation. ( Cummins, DL; Gaspari, AA, 2004) |
| "Thalidomide is a potent anti-inflammatory drug in patients with SLE and cutaneous LE, possibly interacting with the recruitment of lymphocytes." | 1.31 | Clinical and immunologic parameters during thalidomide treatment of lupus erythematosus. ( Messer, G; Meurer, M; Plewig, G; Walchner, M, 2000) |
| "Treatment with thalidomide resulted in a dramatic clearing of skin lesions but failed to improve pathological laboratory tests." | 1.27 | [Treatment of subacute cutaneous lupus erythematosus with thalidomide]. ( Volc-Platzer, B; Wolff, K, 1983) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (10.26) | 18.7374 |
| 1990's | 6 (15.38) | 18.2507 |
| 2000's | 14 (35.90) | 29.6817 |
| 2010's | 8 (20.51) | 24.3611 |
| 2020's | 7 (17.95) | 2.80 |
| Authors | Studies |
|---|---|
| Rizvi, SK | 1 |
| Chong, BF | 1 |
| Sherman, MA | 1 |
| Srinivasalu, H | 1 |
| Kirkorian, AY | 1 |
| Cardis, MA | 1 |
| Chen, PH | 1 |
| Tung, HH | 1 |
| Lin, CH | 1 |
| Huang, KP | 1 |
| Ni, YL | 1 |
| Lin, CY | 1 |
| Wang, X | 3 |
| Li, M | 1 |
| Zeng, X | 1 |
| Wang, Q | 1 |
| Yuki, EFN | 2 |
| Silva, CA | 1 |
| Aikawa, NE | 2 |
| Romiti, R | 2 |
| Heise, CO | 2 |
| Bonfa, E | 2 |
| Pasoto, SG | 2 |
| Lu, Z | 1 |
| Su, D | 1 |
| Li, X | 1 |
| Da, Z | 1 |
| Soares, R | 1 |
| Kupa, LVK | 1 |
| Arnone, M | 1 |
| Pedrosa, TDN | 1 |
| Silva, CAAD | 1 |
| Hara, D | 1 |
| Akiyama, H | 1 |
| Nukui, S | 1 |
| Shimizu, T | 1 |
| Hoshikawa, M | 1 |
| Hasegawa, Y | 1 |
| Ichiyama, S | 1 |
| Hoashi, T | 1 |
| Kanda, N | 1 |
| Hashimoto, H | 1 |
| Matsushita, M | 1 |
| Nozawa, K | 1 |
| Ueno, T | 1 |
| Saeki, H | 1 |
| Liu, J | 1 |
| Yang, X | 1 |
| Yan, Q | 1 |
| Wang, S | 2 |
| Han, W | 1 |
| Wang, D | 1 |
| Chen, H | 1 |
| Zou, Y | 1 |
| Li, J | 1 |
| Pan, J | 1 |
| Ren, T | 1 |
| Zhang, Y | 1 |
| Chen, Z | 1 |
| Feng, X | 1 |
| Sun, L | 1 |
| Wu, EY | 1 |
| Schanberg, LE | 1 |
| Wershba, EC | 1 |
| Rabinovich, CE | 1 |
| Shimanovich, I | 1 |
| Merl, V | 1 |
| Zillikens, D | 1 |
| Grabbe, J | 1 |
| Rose, C | 1 |
| Okoli, K | 1 |
| Irani, F | 1 |
| Horvath, W | 1 |
| Berk, DR | 1 |
| Miller, A | 1 |
| Scarlett, D | 1 |
| Wippold, FJ | 1 |
| Bayliss, SJ | 1 |
| Lu, D | 1 |
| Braunstein, I | 1 |
| Goodman, NG | 1 |
| Rosenbach, M | 1 |
| Okawa, J | 1 |
| Shah, A | 1 |
| Krathen, M | 1 |
| Kovarik, CL | 1 |
| Luning Prak, E | 1 |
| Werth, VP | 1 |
| Housman, TS | 1 |
| Jorizzo, JL | 1 |
| McCarty, MA | 1 |
| Grummer, SE | 1 |
| Fleischer, AB | 1 |
| Sutej, PG | 1 |
| Alfadley, A | 1 |
| Al-Rayes, H | 1 |
| Hussein, W | 1 |
| Al-Dalaan, A | 1 |
| Al-Aboud, K | 1 |
| Pałgan, K | 1 |
| Pałgan, I | 1 |
| Dziedziczko, A | 1 |
| Cummins, DL | 1 |
| Gaspari, AA | 1 |
| Silingardi, M | 1 |
| Iotti, M | 1 |
| Trenti, C | 1 |
| Salvarani, C | 1 |
| Iori, I | 1 |
| Braddock, M | 1 |
| Murray, C | 1 |
| Volc-Platzer, B | 1 |
| Wolff, K | 1 |
| Naafs, B | 1 |
| Bakkers, EJ | 1 |
| Flinterman, J | 1 |
| Faber, WR | 1 |
| Scolari, F | 1 |
| Harms, M | 1 |
| Gilardi, S | 1 |
| Burrows, NP | 1 |
| Singer, NG | 1 |
| McCune, WJ | 1 |
| Ordi, J | 1 |
| Cortes, F | 1 |
| Martinez, N | 1 |
| Mauri, M | 1 |
| De Torres, I | 1 |
| Vilardell, M | 1 |
| Gompel, A | 1 |
| Frances, C | 1 |
| Piette, JC | 1 |
| Blanc, AS | 1 |
| Cordoliani, F | 1 |
| Piette, AM | 1 |
| Flageul, B | 1 |
| Wallach, D | 1 |
| Cavelier-Balloy, B | 1 |
| Bachelez, H | 1 |
| Carsuzaa, F | 1 |
| Dubertret, L | 1 |
| Walchner, M | 1 |
| Meurer, M | 1 |
| Plewig, G | 1 |
| Messer, G | 1 |
| Rao, DG | 1 |
| Kane, NM | 1 |
| Oware, A | 1 |
| Grosbois, B | 1 |
| Duguet, C | 1 |
| Karim, MY | 1 |
| Ruiz-Irastorza, G | 1 |
| Khamashta, MA | 1 |
| Hughes, GR | 1 |
| Pouaha, J | 1 |
| Martin, S | 1 |
| Trechot, P | 1 |
| Truchetet, F | 1 |
| Barbaud, A | 1 |
| Schmutz, JL | 1 |
| Bessmertny, O | 1 |
| Pham, T | 1 |
| Bessis, D | 1 |
| Guillot, B | 1 |
| Monpoint, S | 1 |
| Dandurand, M | 1 |
| Guilhou, JJ | 1 |
| Hawkins, DF | 1 |
| Kewitz, H | 1 |
6 reviews available for thalidomide and Lupus Erythematosus, Systemic
| Article | Year |
|---|---|
Thalidomide and Lenalidomide for Refractory Systemic/Cutaneous Lupus Erythematosus Treatment: A Narrative Review of Literature for Clinical Practice.
Topics: Humans; Lenalidomide; Lupus Erythematosus, Cutaneous; Lupus Erythematosus, Systemic; Retrospective S | 2021 |
Multiple myeloma and systemic lupus erythematosus in a young woman.
Topics: Adult; Dexamethasone; Female; Humans; Immunoglobulin A; Immunosuppressive Agents; Lupus Erythematosu | 2009 |
[Thalidomide--a new prospective therapy in rheumatology and transplantation].
Topics: Arthritis, Rheumatoid; Behcet Syndrome; Graft vs Host Disease; Humans; Immunosuppressive Agents; Int | 2003 |
Update on immunosuppressive therapy.
Topics: Adult; Arthritis, Juvenile; Azathioprine; Behcet Syndrome; Child; Cladribine; Cyclophosphamide; Cycl | 1998 |
Update on therapy--thalidomide in the treatment of lupus.
Topics: Humans; Immunosuppressive Agents; Lupus Erythematosus, Discoid; Lupus Erythematosus, Systemic; Thali | 2001 |
Thalidomide use in pediatric patients.
Topics: Adolescent; Child; Chronic Disease; Female; Graft vs Host Disease; Humans; Hypnotics and Sedatives; | 2002 |
33 other studies available for thalidomide and Lupus Erythematosus, Systemic
| Article | Year |
|---|---|
Cost minimization analysis of mainstay treatments in cutaneous lupus erythematous.
Topics: Aged; Costs and Cost Analysis; Humans; Immunosuppressive Agents; Lupus Erythematosus, Cutaneous; Lup | 2022 |
Clinical Images: Chronic, refractory childhood-onset cutaneous lupus erythematosus of the face responsive to lenalidomide.
Topics: Child; Humans; Lenalidomide; Lupus Erythematosus, Cutaneous; Lupus Erythematosus, Discoid; Lupus Ery | 2023 |
A case report of secondary synchronous diagnosis of multiple myeloma and systemic lupus erythematosus after breast cancer treatment: A CARE-compliant article.
Topics: Aged; Antibodies, Monoclonal; Breast Neoplasms; Female; Glycoproteins; Humans; Hydrocortisone; Hydro | 2022 |
Lenalidomide for systemic lupus erythematosus with refractory cutaneous eruptions.
Topics: Exanthema; Humans; Lenalidomide; Lupus Erythematosus, Cutaneous; Lupus Erythematosus, Systemic; Thal | 2023 |
LABD-like manifestation in a patient with systemic lupus erythematosus.
Topics: Cyclophosphamide; Female; Glucocorticoids; Humans; Immunosuppressive Agents; Linear IgA Bullous Derm | 2021 |
One-year prospective nerve conduction study of thalidomide neuropathy in lupus erythematosus: Incidence, coasting effect and drug plasma levels.
Topics: Adult; Female; Humans; Incidence; Lupus Erythematosus, Cutaneous; Lupus Erythematosus, Systemic; Mal | 2021 |
Utility of osteosclerotic lesion biopsy in diagnosis of POEMS syndrome: A case report.
Topics: Arthritis, Rheumatoid; Cell Proliferation; Diagnosis, Differential; Female; Humans; Immunoelectropho | 2017 |
Psoriasis vulgaris associated with systemic lupus erythematosus successfully treated with apremilast.
Topics: Administration, Oral; Adult; Antibodies, Antinuclear; Drug Therapy, Combination; Female; Humans; Lup | 2019 |
Investigating the role of angiogenesis in systemic lupus erythematosus.
Topics: Adult; Angiogenesis Inhibitors; Autoantibodies; Biomarkers; Endostatins; Female; Fibroblast Growth F | 2015 |
Thalidomide treatment in cutaneous lesions of systemic lupus erythematosus: a multicenter study in China.
Topics: Adolescent; Adult; Blood Sedimentation; China; Constipation; Dose-Response Relationship, Drug; Exant | 2016 |
Lenalidomide for refractory cutaneous manifestations of pediatric systemic lupus erythematosus.
Topics: Adolescent; Female; Humans; Immunologic Factors; Lenalidomide; Lupus Erythematosus, Cutaneous; Lupus | 2017 |
[Two faces of Janus. Coexistence of systemic lupus erythematosus and psoriasis in the same patient].
Topics: Acitretin; Adult; False Negative Reactions; Female; Humans; Immunosuppressive Agents; Keratolytic Ag | 2010 |
Osseous metaplasia late in the course of nephrogenic systemic fibrosis.
Topics: Adult; Analgesics; Calcinosis; Disease Progression; Female; gamma-Aminobutyric Acid; Humans; Hydroxy | 2010 |
Lenalidomide therapy in treatment-refractory cutaneous lupus erythematosus: histologic and circulating leukocyte profile and potential risk of a systemic lupus flare.
Topics: Adult; Female; Humans; Lenalidomide; Leukocytes; Lupus Erythematosus, Cutaneous; Lupus Erythematosus | 2012 |
Low-dose thalidomide therapy for refractory cutaneous lesions of lupus erythematosus.
Topics: Adult; Aged; Dermatologic Agents; Female; Humans; Lupus Erythematosus, Cutaneous; Lupus Erythematosu | 2003 |
Thalidomide for treatment of severe generalized discoid lupus lesions in two patients with systemic lupus erythematosus.
Topics: Adult; Dermatologic Agents; Dose-Response Relationship, Drug; Humans; Lupus Erythematosus, Discoid; | 2003 |
Photoprotection by thalidomide in patients with chronic cutaneous and systemic lupus erythematosus: discordant effects on minimal erythema dose and sunburn cell formation.
Topics: Adult; Female; Humans; Immunosuppressive Agents; In Situ Nick-End Labeling; Lupus Erythematosus, Dis | 2004 |
Thalidomide, deep venous thrombosis and vasculitis.
Topics: Aged; Female; Humans; Lupus Erythematosus, Systemic; Thalidomide; Vasculitis; Venous Thrombosis | 2004 |
10th anniversary Inflammation and Immune Diseases Drug Discovery and Development Summit. 20-21 March 2006, New Brunswick, USA.
Topics: Animals; Anti-Inflammatory Agents; Asthma; Clinical Trials as Topic; Drug Delivery Systems; Drug Des | 2006 |
[Treatment of subacute cutaneous lupus erythematosus with thalidomide].
Topics: Azathioprine; Biopsy; Fluorescent Antibody Technique; Humans; Immunoglobulin G; Immunoglobulin M; Ki | 1983 |
Thalidomide treatment of subacute cutaneous lupus erythematosus.
Topics: Humans; Lupus Erythematosus, Systemic; Male; Middle Aged; Thalidomide | 1982 |
[Thalidomide in the treatment of chronic lupus erythematosus].
Topics: Adult; Aged; Chemical Phenomena; Chemistry; Chronic Disease; Female; Humans; Lupus Erythematosus, Sy | 1982 |
Diagnosis and management of systemic lupus erythematosus. Thalidomide modifies disease.
Topics: Humans; Lupus Erythematosus, Systemic; Thalidomide | 1993 |
Thalidomide induces amenorrhea in patients with lupus disease.
Topics: Adult; Amenorrhea; Female; Humans; Immunosuppressive Agents; Lupus Erythematosus, Discoid; Lupus Ery | 1998 |
Ovarian failure with thalidomide treatment in complex aphthosis: comment on the concise communication by Ordi et al.
Topics: Adult; Amenorrhea; Female; Humans; Immunosuppressive Agents; Lupus Erythematosus, Systemic; Lupus Vu | 1999 |
[Thalidomide and thrombosis].
Topics: Adult; Dermatitis, Atopic; Female; Humans; Immunosuppressive Agents; Lupus Erythematosus, Cutaneous; | 2000 |
Clinical and immunologic parameters during thalidomide treatment of lupus erythematosus.
Topics: Adult; Antibodies, Antinuclear; C-Reactive Protein; Complement System Proteins; Enzyme-Linked Immuno | 2000 |
Thalidomide neuropathy: role of F-wave monitoring.
Topics: Adult; Aged; Female; Humans; Immunosuppressive Agents; Lupus Erythematosus, Systemic; Neural Conduct | 2000 |
[Thalidomide: the revival].
Topics: Angiogenesis Inhibitors; Behcet Syndrome; Humans; Immunosuppressive Agents; Lupus Erythematosus, Sys | 2001 |
[Thalidomide and thrombosis: three observations].
Topics: Adult; Aged; Behcet Syndrome; Histiocytosis, Langerhans-Cell; Humans; Immunosuppressive Agents; Lupu | 2001 |
Thalidomide for systemic lupus erythematosus.
Topics: Adult; Female; Humans; Lupus Erythematosus, Systemic; Thalidomide | 1992 |
Thalidomide for systemic lupus erythematosus.
Topics: Abnormalities, Drug-Induced; Female; Humans; Lupus Erythematosus, Systemic; Pregnancy; Thalidomide | 1992 |
[Drugs as cause of diseases].
Topics: Abnormalities, Drug-Induced; Berlin; Contraceptives, Oral; Cortisone; Drug-Related Side Effects and | 1974 |